Wave Life Sciences Ltd. - Jefferies Global Healthcare Conference in London - WAVE LIFE SCIENCES INC
Welcome, everyone, to 2026 Jeffries Global Healthcare Conference in London. My name is Roger Song, senior, and I cover Semicat Biotech in the U.S. It is my great pleasure to have the five-star chat with Wave Life Sciences, and we have a CEO, Paul Bommel. Welcome. Roger, thanks for having us. Awesome. All right, I think we have enough to cover. Why don't we just go right into it? So, in heavy use, you'll be probably top of the people's mind. We just came back from the Obesity Week, a lot of the non-incretin, amyloid activity there. Most of them are preclinical. You are leading the pack there. Maybe just start with that. So I don't know if you were there, but at least your team probably have some key takes for you. That's the same way in the presence. Yeah, that's right. So what is your key take from this ObesITY Week and then related to your program? Yeah, no, and it's a very timely conversation because, you know, this time of year we get to reflect both on last year and then this year. And if we think about kind of the evolution, I think, at Obesity Week, if last year was this focus on there was this race to what we call, you know, it was almost like a nuclear arms race to, like, weight reduction almost at any expense, with the opening that people were recognizing that there is different quality, like how do we think About Fat, how do we think about muscle, but there were a number of programs. I'd say this year was palpably a shift towards a focus on kind of two areas of importance, and I think they line up, to your point, exquisitely well with the mechanism of inhibiting and the path we're taking, which is, one, a real reflection on quality of weight loss and body composition, so discussion on what do we really mean when we say weight loss? Are we talking about scale weight loss, or are we really talking about body composition improvement, meaning fat loss, visceral fat, subcutaneous fat, but lean mass preservation. I think that was a key driver. I think there's a realization from the KOLs in the space that this idea of losing lean mass at the expense of kind of a number and percent body weight reduction isn't the answer to solving the crisis, and realizing that actually keeping and retaining lean muscle mass actually potentiates further fat reduction and fat maintenance because it's an endocrine organ involved in insulin sensitivity. So that concept of quality of weight loss, body composition was one feature. I think the other conversation, which again is also very timely for inhimany, is a real conversation that now with incretins on the market so long and with the idea that it's kind of now ubiquitous, people talk about it all the time, is the conversation really evolving to my patient achieved whatever this goal is right and then you know person you know we see this even in individual conversations with people who are self-prescribed like I'm at my goal like there's this desire of getting to whatever that is for various different individuals what's next and I think that conversation that physicians and patients are really starting to have and frankly payers for that matter are saying we we're getting this health benefit but the health benefit is only sustained if a patient stays at a particular moment in time. I think what we're seeing now is this notion of what do we do? Because 70% of patients aren't staying on there and creating every, I mean, we know that people are coming off of those medicines, and we know there's a lot of hesitancy of what that transition looks like. So this concept, and there's different ways of calling it, you know, we like to refer to that as maintenance. What does maintenance of this weight loss look like? And so if we think about kind of the two most important pillars of what inhibini can do. You know, one is body composition improvements and what you see mechanistically when you have a medicine that drives loss of fat and preservation of muscle. And then secondly, so long as that effect's sustained in opportunity, I think these are the two really most interesting areas for inhibini therapies. And, you know, we could talk about, and I think it's important to spend time, and we can do that afterwards, on kind of the genetics of the target, the data on the target and why we think this target has implications for both body composition improvements and also what maintenance starts to look like long-term to realize real health outcome benefits for patients and payers. Excellent. As always, you teed up pretty well. And then I think we can pass out a couple components you just mentioned, the comments. First of all, the high-quality weight loss, right? And then you are running a phase 2 trial and then, you know, try to enroll the patient with a little bit higher BMI, which we're likely going to see more benefit from the inhibiting mechanism because it's more fat-driven, you're not fat-loss-driven. What's your target there, right, because, you now, in this population, they're a little heavier and with more fat to lose, but eventually you still need to see the weight loss and then how this body composition, the lean versus the fat loss, kind of play into the place, make your overall weight loss even more impressive if number-wise it's lower than the incutin. Yeah, and I think this is the evolution of weight loss versus body composition improvement and what does that look like in a vis-a-vis scale weight. Nonetheless, we'll talk about like what people really refer to oftentimes on weight loss is trying to think about regulatory thresholds. threshold. So what needs to be achieved to various thresholds? So I think stepping back to this point, because there's a lot to digest in the question and kind of how to think about it in various segments. So I mean, I think a lot of this is about what I call the first segment. So this is the kind of, it's oftentimes referred to as kind of the monotherapy. And I think if we're thinking about it differently, because I could argue maintenance is also monotherapy, there's an induction discussion of really what do you need to drive this improvement. So that's the induction component of the drug. There's the combination, and we have a lot of conversations about the idea of what happens when these mechanisms are combined and the ability of what does that mean long-term to actually reducing and kind of down-titrating doses of incretins that, you know, some strategists will often refer to this as their definition of maintenance, which is maintaining people on GLP-1s potentially at a lower dose alongside inhibiting to improve body composition. But the third is this maintenance concept of how do you sustain people on this drug. So if we kind of start with the first one, which is where a lot of that question sits, which is what does that induction component look like on a driver of body composition? I mean, I think the regulatory threshold for an approval is still 5% change in total body weight. I think what we want to see, so if we can kind of go back to the early data, and what I can say is stepping back across all the cohorts in this study, What we do see is there's a high correlation between baseline adiposity and therapeutic effect. Now, that's important because that's consistent with everything we've seen both preclinically and if we think about the human genetics. But if we thing about preclinkly and we share these data at our most recent R&D day, and I'm going to flip the order of what people are usually used to, if we take a lean mouse that's fed a lean diet and we give them inhibini, it's not surprising they don't lose weight. They don't have fat to lose. If we take a DIO mouse model, which is a representation of an obese mouse model fed a high-fat diet, they have the same body weight reduction as GLP-1s, albeit at a slower rate because they're not doing that 30% to 40% lean mass loss at the beginning, and so with an improvement in body composition. So in that weight loss model, we see that coming off of visceral fat, subcutaneous fat, lean mass preservation that's what we saw if we go back to like the the most representative population in the study was the 240 that's the group that had the highest baseline adiposity that we could we could evaluate on bmi and that group we saw 15 reduction in visceral fat three point five point three percent reduction in total body fat three three percent decrease in waist circumference so we think about inhibiting data in general that's out there it's the most comprehensive data set on the target in that it was visceral fat it was total fat it was waist circumference and so kind of the constituency of things you need to see all with preservation of lean mass and that's that's important as we think about this this mechanism is one that drives fat reduction so for those unfamiliar with inhibini human genetic target 50 percent loss of function yields and these can manage this is the human maintenance study if you're born that way you don't accumulate abdominal visceral fat or body habit, increased sub-Q fats. These are patients who are generally lean and body habitist. They have low lipid profile, so a beneficial lipid profiling. And they have, in the outcome studies, because in the U.K. Biobank, they followed these patients out, they have cardiovascular outcome benefits and type 2 diabetes outcome benefits. So if we imagine that human experience, we could recapitulate that on fat reduction and lean body mass preservation. That's in the monotherapy. We could also show in combo when you add it, you see that reduction additive to the GLP-1. You double the weight loss. And, again, the mechanism is all fat. So you don't see further loss of lean mass in combination. You just see further fat reduction, which drives body weight reduction. But probably when – and you will hear me say this again. I think the most interesting data set that was emerging, which is consistent with the human genetics, is the maintenance data we ran, where we did the induction. we had these mice at a steady state of weight loss on semaglutide. We dosed with inhibini and withdrew the semarm, and there's a placebo and inhibini. Both mice, importantly, so this gets back to the mechanism, went back to hedonic eating. So the caloric consumption went up in both animal groups. And the tree group stayed flat. They did not reaccumulate fat, with exception of a small bump in body weight, which actually now we know, is just an increase in the lean muscle mass that they kind of get to restore. We know that stabilizes, but don't regain fat. And if we think about what happens to patients in this coming out of Obesity Week, is the most dangerous thing for patients in obesity is weight cycling, meaning you go on these therapies, these patients go through a high degree of loss. When they regain their weight back, everybody goes, oh, they regain Their weight back to starting or a little bit higher than baseline, exactly what happened to these mice. But what's interesting is when that weight comes back, it comes back as fat, not as muscle. So actually, these patients oftentimes have a higher degree of adiposity at the end of the study than when they actually started their therapy to begin with. And that's why when people talk about weight cycling as being potentially dangerous, the goal is that this accumulation of fat continues. The whole mechanism of inhibite is to prevent fat accumulation. And one of the interesting things to come out of the recent data update we did going into Obesity Week is we saw the 240, which is our 12-month follow-up period, that active and E levels were sustained out at a year. So again, reinforcing our differentiation on siRNA for potential once- to twice-a-year dosing. What we also saw was the body composition of those patients stayed stable. So again this is a Phase I study. We have no diet or exercise requirements, hence why we talk about the beginning. But if we think mechanistically, it's highly encouraging that what was supposed to happen mechanistically if you suppress active and is continuing to play out. So I think this idea of where we're going directionally with body composition is important on this induction. But I do think about long-term, how are we actually addressing the longitudinal treatment of patients with obesity? The notion of this is the maintenance therapy is pretty important. Yeah, okay. A couple quick pointed questions on the induction monotherapy. How should we think about if you show 5% weight loss but most of them are, if not all of them, are coming from fat, would that be exciting for you to move forward as a monotherapy? Or on the other side, you can combine these combinations, and I think we saw other in Hebei, double whatever that Inquitin can achieve. That would be more important to move toward. Yeah, I think, and coming out of a number of meetings, I'm interested to hear, I Think 5% is kind of where, That's a regulatory bar for obesity. I think it's less about is it 5%, is it 6%. The absolute scale weight percentage, it's what's the quality of that weight loss. And I think what is exciting about what 5% means is it's not 5% on a scale where people go, well, I'm looking at incretins and is 5% really meaningful. If we look at the Believe data set at the first time point when they cut it, like 30% to 40% of that body weight reduction is all lean skeletal muscle. Like that's lean mass loss coupled with fat. If what we're seeing over time is a substantial change in body weight, take 5%. But all of that weight, and if we think about the differential between how much a pound you lose in fat versus what a pound do you need to lose in terms of muscle, like they're very different in what that changes for individuals. So 5% body weight reduction, that's all coming off of fat, subcutaneous fat, visceral fat, is a substancial shift for these patients. That's why, frankly, the agency uses that as the cutoff because it's in their belief, right, that that was an evaluation that that would be clinically meaningful reduction in total body weight. What's also important, if we go back to the FDA guidance of the 5%, is the FDA doubling down on quality of the weight loss that's delivering that. You know, I think it's really to address this notion that what's damaging to individuals long-term in health is subcutaneous fat and visceral fat. And so a substantial reduction would absolutely be clinically meaningful to these individuals if they could take a dose where we're looking, again, about a medicine that you get once or twice a year that could cause a substantial shift in outcomes benefits, which would come from that percent body weight reduction. And how should we think about the kinetics? Because the trial is going to run longer term, but when you're going to update the street, I think you say you're gonna decide if you will release the three-month data. But, you know, we know three months probably is the body composition more likely. What's going to trigger you to release data early? And then how should we think about the six months and nine months without getting towards the 5% and make this more achievable at the 12 months? Yeah, I think it's a great question because it was what we wanted to answer sooner rather than later. So, you Know, on Friday we provided the update going into Obesity Week. we were clear in that announcement that you know we would say look at the six month data um one we wanted to take out any doubt that we're looking at data and making that decision so it's blinded study we're not um but two exactly to your point um i think we can all reflect on past data release so that you we know that this has a body composition improvement we know to your point on what are people looking for beyond just body composition they're looking for shifts that kind of project towards what could be a regulatory achievable outcome. And to that end, three months is a very clear body composition time point. We see that in every study that we've run on this, that the early time point, lean muscle mass goes up. That's awesome. You want that to happen. That means these patients are actually getting muscle mass restoration, and they're losing fat. That'S also important. But it's a mathematical equation that if you gain muscle and you lose fat, that that gain in muscle offsets that change. By six months, if I reflect on this conference kind of sitting last year where there was a lot of enthusiasm at body composition shifts and we saw the lean mass go up and we Saw Fat come down and I think there was lot of enthousiasm, we reminded people, like, the biggest concern at that conference discussion was is lean mass going to keep going up? And, you know, is it going to become harder and harder to see the algebra work out to how are you going to see percent body weight reduction. And we were very clear at that point in time that every study we've run that we've seen in other medicines that have mechanisms that are similar in terms of lean mass preservation, that by three months you see a plateauing of lean muscle mass. And that's exactly what we saw. We had the data release in March. Lean mass has plateaued, so it didn't continue to get higher. And body fat reduced. And that concept of if we look out and why the six-month data becomes important is that's where the card gets turned over. And then to your point, it's six months, nine months, 12 months. That drives an equation where lean mass stays the same. Fat should continue so long as activity is suppressed, like we've seen before. And so long is the baseline adiposity is there, you should continue to see that. Hopefully, it was helpful to us. We shared this at earnings recently that we did do because, you know, the question in the minds are all, what's the baseline characteristics looking like going into the study? You know, we believe that it would be pretty clear that when you run an obesity 2-3 study, patients have very similar characteristics going there. And if you picture that slide where there's a box at the top, there's a clustering of not just BMI increases, but importantly, that translating that increases in adiposity, visceral fat, and subcutaneous fat. We did provide the update that not only is the BMI consistent in this enrollment, as we're saying, so these patients have high BMIs, as would be expected, in the study. So that's important. But because we have baseline MRI, we also did the QC on baseline adiposity. And what we could say is that is correlating that these patients do have higher baseline adipocity in addition to high BMI. So as we kind of set a study up for a medicine whose whole purpose is to reduce fat off of that higher adipocyte, which is what we saw in the phase one, I think it's encouraging that the study is set up to deliver the patient population that we need to study in with the mechanism that we have. So based on the baseline characteristics and then your previous phase one data in a relatively healthy patient and then you're PKPD modeling, do you expect the six months will getting closer to 5% or the whole lineality after six months to 12 months? Because the ultimate goal is 12 months to 5%. Just be clear, right? That's the goal. Not changing that goal. Yeah. And then in the six month, you know, it will be more linear with your halfway or it's kind of a plateau from six to 12 month. I don't know if we have the answer for the kinetics. Yeah, I'm always careful of trying to translate mouse kinetics to human kinetics simply because of metabolic rates. I think what's encouraging, I always look back at the DIO and say, look, it translated for incretins. Weight reduction was similar for incretenes, so we know that it can get there now. What that year translation, you know, takes in, we should see that curve shift at six months. I mean, I think we relatively believe that by three months you lose fat and you have still fat to lose at six months and muscle stabilizing, then body weight gets reduced. I mean, again, I think the simplicity of really thinking about it as a mathematical equation of lean mass increases body weight and fat reduction decreases it. And so long as that proportion stays, we should see that curve translate at the six-month time point. And then it becomes easier to project, to your point, on where do we think it will need to be on a timeline. But step one is right patient population. we now have conviction that we're there now it's about following it and I think six months as we said is the right time to do that first look and see where we'll be on that trajectory. And then your maintenance which we agree this is a very important setting to address and then for the what's the what's what's the increase in level at the end of enrolling into the maintenance is that top top dose in at the maximum weight loss and then the goal is to maintain how much maintain will be successful and how likely they can even increase the weight loss no it's a very important question um and the one that the study set up to answer so the update we provided on friday which i think again going to obesity week is really important is i know there was a lot of waiting to see what's the maintenance study going to look like um and i you know give the team an enormous amount of credit for spending time really thinking about efficiency so you know given to your point of needing to do run-ins and think about how do you do that, to think about that as an entirely different trial design when we've already initiated combination as part of this study, right? So there's combination that has trisepatide. So we have a placebo and we have inhibini where we're looking at that monotherapy, right, just trisapatide alone with placebo. And we've got inhibini with trisapatide to look at the additivity. Those patients are all going to reach their nadir, right? That's part of the definition of the combination study is to see the effect size of terzepatide placebo versus inhibinase or the additivity. The view was, rather than waiting again, we've just invested the patient's time in getting to whatever the treatment goal is going to be. So then the advantage is, well, that's great. Now all we have to do is rerun the study we ran in our preclinical models of dose the patient with draw the trisepatide, and then we'll look at the recovery rate. And, you know, one of the interesting things that the experience has taught us, given that a number of these studies have been run across incretins, is the rate of return of body weight post-cessation is pretty fast. So the ability to see signals very early on as to blunting that curve is something we'll be able to capture in that study. And then to that point, that's the advantage then of following those patients out. So that study has a follow-up period of, you know, we can actually follow them up to a year if we want to look at the cessation piece and what maintenance starts to look like. So efficiently within one trial design where those patients are already captured, already being studied, already well part of a clinical trial to look AT the efficacy, we're going to be able to look at that recovery rate on maintenance. And so, you Know, we are excited to do that because the data-to-date is very strong for maintenance. If we think about that area, it's it is an open space where people are trying to figure out what is the best way to do that and the best that people really have come up with is various dosing regimens of medicines that patients don't want to stay on so like from a tolerability and other standpoints so the ability to kind of think orthogonally and say get patients on a once to twice a year medicine so that they can then move forward i think maintenance is a very promising application for this medicine I should say as part of this holistic study, and really to build on the label, inhibin E has a whole bunch of other features that are associated with the genetics beyond just fat reduction. So these patients have improvements in hemoglobin A1C. They have reduced risks of liver disease and liver fat and inflammation. And so part of the study will enable us to actually build on a label for not just a body composition improvement, weight reduction, but actually all of the other orthogonal features that we ascribe to GLP-1s in terms of outcome benefits. So we'll be able to look at type 2 diabetes in this study by looking at hemoglobin A1C levels. We'll be be able look at MASH as a potential indication because we have MRI, PDFF, and we'll looking at liver fat accumulation. So we have to look other lipid levels as well as we think about cardiometabolic profiles. So I think in totality as we come out of this, we were very disciplined that the most important thing to do is make sure if we're going to run this study that we run it where data becomes definitive and usable as opposed to exploratory. And so this study is well-powered for each one of these endpoints to be able to give us a signal, assess that signal, and really come out of this trial with a very clearly defined path forward for where inhibitor E is going to fit as a therapeutic profile. Excellent. All right. So we don't have too much time to talk about the other pipeline, but you got alignment for the AATD, which is, I think, the study design is pretty novel compared to other modalities. So my question, actually, is how likely other AATD programs will get a similar treatment as you got, like the same trial supporting accelerated approval and the full approval? I know you don't want to disclose too much because there's a competitive edge, for sure. But just in terms of this is more unique to WAVE or more unique to RNA editing or something unique? The nice thing is I don't think this is unique to WAVE. I think what was unique is the approach the team took to it. I think too often, and I only have like 20 seconds, but I think it's important. Too often we've seen in rare disease the challenge is everybody runs very quickly to the accelerated approval endpoint. Small number of patients get there very quickly and what i call drop the drawbridge and then what do we see i mean dmd is another great example of this you lower it multiple companies go in to pursue it because the perception is okay the bar is set for everyone now because that's setting a regulatory paradigm and threshold and everybody runs in and then everybody's got to run their confirmatory studies and you know and then continue to oftentimes we see this delay and this lag to getting there and so what i think think was highly efficient about this design was, one, truncate the time to get into a full approval, opening up U.S. and Europe, and as it's at least consistently being seen, MFN in the rare disease place is not playing as big a role, so you really can think about potential for two markets in that opportunity set. By doing that, you've already now enrolled essentially your confirmatory study, so you've got a path forward where you're not trying to find these patients, compete. When you deliver that study, you're now lifting up the drawbridge, and you're saying, Actually, anybody else who's come through actually has to run a superiority study to the approved program, which we've done in a very short period of time. But what, and again, credit and kudos, and I'm looking at Chris and the audience, to the team is we haven't forgone in that conversation what everybody's still looking for, which is interim analysis for potential accelerated approval that you can use on all of that same pathway. So you've been able to kind of feed two birds with one hand, which is the expediency that we often ascribe to accelerated approvals and the efficiency of getting to patients very quickly. But to the end, realizing that in a competitive arena, how quickly can you change the chessboard of what that's going to look like, do that with a well-described study. And I think the challenge for why different companies have an approach is we're not afraid to say, you know what, it's a big enough population, we can run a placebo-controlled study for full approval with endpoints that we like and do that. And what we're seeing, particularly amongst the DNA editing group, is a reluctance to say we need to run these smaller studies with fewer patients. It probably has a lot to do with the cost of therapies, that we can do this with smaller studies potentially without the placebo. And so I think it's really a view that we took that we could do this highly efficiently, highly effectively in a cost-effective manner too to deliver that endpoint and deliver the potential for a registrational accelerated approvals position as well. So, again, I think that's the advantage, and, you know, I do think for anybody who wants to do that, I don't think, you Know, that there's a uniqueness in the agency of saying, like, you know, that's special. You have to have the desire to do both and the plan to do both, and you know if you can execute that, I think that that's going to be best for patients, and I think long-term accelerating this medicine, so I think it's great for the program. Excellent. All right. Thank you so much, Paul. Thank you. Yeah. Thank you, everyone.
- Company
- WAVE LIFE SCIENCES INC
- Keywords
- WAVE LIFE SCIENCES INC